Has Ashley Rawls, MD received payments from drug or device companies?

Yes. Drug and device makers reported $48,066 in general payments to Ashley Rawls, MD across 41 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ashley Rawls, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ashley Rawls, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ashley Rawls, MD

Neurology · Stanford, CANPI 1477968451

Payments from drug & device makers

$48,066in general payments, 2019–2025

Across 41 payments — averaging $1172.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$48K
Boston Scientific$290

What the payments were for

Grants$43,75091%
Travel & lodging$2,9256%
Food & beverage$1,3223%
Education$700%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	38	$47,776
Boston Scientific	3	$290

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,066 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$292,201

Medicare patients

264

Services billed

35,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IngrezzaValbenazine Tosylate	12	$97,452
AustedoDeutetrabenazine	11	$45,696
Carbidopa-LevodopaCarbidopa/Levodopa	167	$6,472
Carbidopa-Levodopa ErCarbidopa/Levodopa	73	$4,959
AmantadineAmantadine Hcl	27	$1,876
Clozapine	38	$1,342
Baclofen	43	$1,082
Clonazepam	43	$830
Atropine Sulfate	16	$786
Gabapentin	28	$744
Propranolol Hcl ErPropranolol Hcl	27	$721
Primidone	13	$514
Pregabalin	21	$427
Ropinirole Hcl	23	$392
Pramipexole DihydrochloridePramipexole Di-Hcl	19	$292

Paid to pharmacies, not to this prescriber.

Other neurology in Stanford

Timothy CloughesyLos Angeles$33.1M
Jack FlorinFullerton$13M
David KudrowSanta Monica$12.8M
John Ravitsla Jolla$8.4M
Perminder BhatiaFresno$8.3M
Perry ShiehLos Angeles$8.2M
Benjamin FrishbergCarlsbad$8.2M
Bruce CreeSan Francisco$8M
Lawrence RechtPalo Alto$6.6M
Stanley PrusinerSan Francisco$6.5M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →